ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Stock data | 2024 | Change |
---|---|---|
Price | $14.05 | N/A |
Market Cap | $1.35B | N/A |
Shares Outstanding | 96.00M | N/A |
Employees | 24.00 | N/A |